Welcome to our dedicated page for OS THERAPIES INCORPORATED news (Ticker: OSTX), a resource for investors and traders seeking the latest updates and insights on OS THERAPIES INCORPORATED stock.
OS Therapies Inc. (OSTX) delivers innovative therapies targeting osteosarcoma and solid tumors through cutting-edge biopharmaceutical research. This page provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access verified information about OSTX's pipeline progress, including clinical trial results, FDA communications, and research partnerships. Our curated news collection helps stakeholders track advancements in pediatric oncology treatments and therapeutic innovations.
Discover updates across key categories: new drug applications, trial phase transitions, scientific collaborations, and patent developments. All content undergoes rigorous verification to ensure alignment with medical reporting standards and financial disclosure requirements.
Bookmark this page for streamlined access to OSTX's latest developments in bone cancer research. Regularly updated to reflect the company's progress in addressing critical unmet needs through targeted therapeutic solutions.
OS Therapies (NYSE-A: OSTX) has partnered with B2i Digital to enhance investor outreach and raise awareness about its cancer immunotherapy research. The company's lead candidate, OST-HER2, is an off-the-shelf immunotherapy targeting HER2-positive cancer cells, currently in Phase 2b trials for recurrent, resected metastatic osteosarcoma. The trial has completed enrollment and patient visits, with clinical data updates expected during the JP Morgan Healthcare Conference 2025.
Additionally, OS Therapies is developing a tunable Antibody-Drug Conjugate (ADC) platform aimed at providing tailored cancer treatments with improved efficacy and reduced side effects. B2i Digital will implement data-driven strategies to communicate the company's progress and upcoming milestones to investors.
OS Therapies (NYSE-A: OSTX) has announced a $6 million private placement, selling 1.5 million units at $4.00 per unit. Each unit includes one share of Series A Senior Convertible Preferred Stock and one warrant to purchase common stock. The Preferred Stock conversion price is $4.00, with warrants exercisable at $4.40 per share.
The placement, expected to close around December 27, 2024, will provide funding into 2026. The proceeds will support clinical and regulatory milestones for OST-HER2, the company's lead therapeutic candidate for recurrent, resected metastatic osteosarcoma. Phase 2b data for OST-HER2 will be announced during the JP Morgan Healthcare Conference in January 2025.
OS Therapies (NYSE-A: OSTX) reported Q3 2024 financial results and business updates. The company completed its IPO and finished dosing the final patient in its Phase 2b clinical trial of OST-HER2 in osteosarcoma. Topline data is expected in December 2024. The trial treated 41 patients across 21 US sites. The company reported a net operating loss of $2.875 million in Q3 2024, compared to $2.006 million in Q3 2023, with a net loss per share of $0.18. OST-HER2 has received Rare Pediatric Disease, Fast Track, and Orphan Drug Designations from FDA and EMA.
OS Therapies (NYSE-A: OSTX) has announced its participation in The Spartan Capital Investor Conference on November 4, 2024, at the Pierre Hotel in New York. CEO Paul Romness and CBO Gerald Commissiong will deliver a corporate overview at 4:45 PM ET and will be available for one-on-one meetings with registered investors.
The conference, organized with B2i Digital, will showcase presentations from over 30 selected companies and feature panel discussions, meetings, and networking opportunities. This participation demonstrates OS Therapies' commitment to engaging with industry leaders and investors.
OS Therapies (NYSE: OSTX) announces an exclusive live investor webinar scheduled for October 30, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature presentations from CEO Paul Romness and CBO Gerald Commissiong focusing on the company's novel treatments for Osteosarcoma and solid tumors through OST-HER2 and OST-tADC candidates. The company highlights potential near-term revenue opportunities including out-licensing deals for canine OS ($15M+), human OS ($100M+), OST-tADC SiLinkers™ ($20-80M), and a priority review voucher valued at $100-110M.
OS Therapies (NYSE American: OSTX), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, has announced its participation in the LD Micro Main Event XVII. CEO Paul Romness and CBO Gerald Commissiong will deliver a corporate overview presentation on Tuesday, October 29, 2024, at 11:30 AM PT at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference runs from October 28-30, 2024. Both executives will be available for one-on-one meetings with registered conference investors.
OS Therapies (NYSE American: OSTX), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's CEO, Paul Romness, will be presenting in a fireside chat during the event.
Key details of the presentation:
- Event: Fireside Chat at 2024 Maxim Healthcare Virtual Summit
- Date: Thursday, October 17, 2024
- Time: 3:00 PM ET
The summit is scheduled to take place virtually from October 15 to 17, 2024. Interested parties can access the webcast of the fireside chat through the provided link: https://m-vest.com/events/healthcare-10152024
OS Therapies (NYSE American: OSTX) announces the completion of the treatment period for its AOST-2121 Phase 2b clinical trial of OST-HER2 in recurred, resected Osteosarcoma. The last patient has completed their final 52-week radiographical evaluation. The company is preparing to request a Type C Meeting with the FDA and make any necessary protocol adjustments before locking the clinical trial database for data analysis.
The topline data readout is expected in Q4 2024. OST-HER2 is designed to prevent metastasis, delay recurrence, and increase overall survival in Osteosarcoma patients. The trial involved 41 patients across 21 U.S. sites, with primary endpoints of Event Free Survival at 12 months and Overall Survival at 36 months. OS Therapies will ring the closing bell at the NYSE, with CEO Paul Romness scheduled for interviews on Fintech.TV and the Schwab Network on October 3, 2024.
OS Therapies (NYSE American: OSTX) has announced the development of two novel tunable Antibody Drug Conjugate (tADC) therapeutic candidates using its proprietary SiLinker™ technology. The first candidate targets Breast, Lung, and Gastric Cancer, while the second focuses on platinum-resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. The company has completed target engagement tests for both candidates, confirming their therapeutic potential.
OS Therapies aims to advance its tADC platform through product development milestones and plans to out-license certain therapeutic candidates and components, particularly the ph-sensitive SiLinker™. The company's first tADC asset, OST-tADC-FRα-H, has achieved proof of concept in animal models of ovarian cancer. With these new additions to its pipeline, OS Therapies is positioning itself as a key provider of intellectual property for new therapeutic product development to partners.
OS Therapies (NYSE American:OSTX) has announced positive preclinical data for its ovarian cancer therapeutic candidate developed using its proprietary tunable Antibody Drug Conjugate (tADC) platform. The candidate, OST-tADC-FRA-H, combines a folate receptor alpha targeting small molecule with hexa-exatecan payloads linked by the company's SiLinker™ technology.
Key findings include:
- Strong antitumor activity in KB and IGROV-1 mouse models of ovarian cancer
- Excellent safety profile with no bodyweight loss compared to control animals
- Potential to improve safety and efficacy of existing ADC combinations
This proof-of-concept study paves the way for developing multiple tADC-based drug candidates for preclinical and clinical evaluation, potentially revolutionizing ADC construction.
FAQ
What is the current stock price of OS THERAPIES INCORPORATED (OSTX)?
What is the market cap of OS THERAPIES INCORPORATED (OSTX)?
